Almirall announces ADlong results as Almirall stock matches EUR 10.27 Xetra close
Published on 10/04/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 1, 2026, Almirall announced long-term ADlong results for lebrikizumab in moderate-to-severe atopic dermatitis through a company release. On October 4, 2026, Almirall stock was EUR 10.27 in weekend trading at Lang & Schwarz at 5:36 p.m. CEST, unchanged at 0.00 percent versus the EUR 10.27 close of the last Xetra trading day at Lang & Schwarz on October 2, 2026.
Weekend trading at Lang & Schwarz
The bid was EUR 10.20 and the ask was EUR 10.34 at the quoted time. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CEST is shown by the continuously updated real-time quote of Almirall stock.
ADlong study reports sustained responses
Almirall said the Phase 3b open-label extension study evaluated adults and adolescents who received lebrikizumab for up to five years across the clinical development program. At week 108, 92.9% of patients achieved an EASI-75 response and 73.8% achieved EASI-90. The company also reported that 66.7% achieved clear or almost-clear skin and 78.0% recorded a pruritus score of four or less. The release said the safety profile during the 108 weeks was consistent with previous studies and that no new safety signals were identified. Five participants, or 2.9%, discontinued because of treatment-emergent adverse events, while 5.7% experienced serious treatment-emergent adverse events; no deaths were reported. These findings were presented at the 35th European Academy of Dermatology and Venereology Congress in Vienna.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
